News and articles related to topics including Global Infectious Diseases: Prevention, Preparedness and Response and the China-US Relations conference.
The CRE "superbug" has successfully reached hospitals from coast to coast here in the U.S. Treatment is difficult for this family of germs, so it's important to know what to look out for and how to avoid it in any health care facility.
Gerald Parker, D.V.M., Ph.D., vice president for public health preparedness and response at Texas A&M Health Science Center and principal investigator of the Texas A&M Center for Innovation in Advanced Development and Manufacturing, will serve as the keynote speaker on February 10 at an international symposium to commemorate the establishment of the Biodefense Research Institute at Korea University.
Last year marked the beginning of the worst measles outbreak in two decades for the United States. The preventable disease once thought to be eradicated from U.S. soil has many people wondering how something like this could have happened.
Gerald Parker, D.V.M., Ph.D., vice president for public health preparedness and response at Texas A&M Health Science Center, was recently appointed to serve as an ex officio member of the Blue Ribbon Study Panel on Biodefense.
Texas A&M Health Science Center solidifies growth trajectory with unprecedented research expenditures milestone
With an unprecedented 34 percent increase in 2014, Texas A&M Health Science Center has crossed the $100 million threshold in total annual research expenditures, which includes a nearly 68 percent increase in funding from federal sources.
Wielding Nature’s Sword: Researchers at Texas A&M discover new treatments against drug-resistant infections
Since World War II, antibiotics have been our only defense against bacterial infection, but overuse and misuse have caused some bacteria to develop resistance to antibiotics. Now, researchers at Texas A&M Health Science Center have discovered an entirely new class of antimicrobials that have the potential to kill drug-resistant bacteria.
College of Medicine announces new department to bridge gap between clinical excellence and scientific discovery
Approved by the Texas Higher Education Coordinating Board, a new Department of Clinical Translational Medicine will serve as an academic home for clinical teaching and physician-scientist faculty within the Texas A&M College of Medicine, and will provide the infrastructure for new degree programs as the college continues to expand.
Texas Governor Rick Perry, Texas A&M University System Chancellor John Sharp, Texas A&M Health Science Center CEO Brett Giroir, M.D., and officials from the U.S. Department of Health and Human Services (HHS), State of Texas and biopharmaceutical company GSK dedicated a national pandemic influenza vaccine manufacturing facility in Bryan, Texas, which when complete will serve as an anchor for the Texas A&M Biocorridor – a rapidly evolving hub of economic development and scientific discovery that is swiftly positioning Texas as the third coast in biotechnology.
Researchers at the Texas A&M Health Science Center (TAMHSC) and the University of Texas MD Anderson Cancer Center have developed a new therapy to stimulate the body’s natural immune system, thereby providing effective protection against a wide range of life-threatening infectious diseases.